TCGA-68-A59I-01A-11R-A262-07
— · cohortSQ1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ1
- subtype
- cohortSQ1
- age_years
- 73
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- HEDGEHOG_SIGNALING+0.390
- WNT_BETA_CATENIN_SIGNALING+0.370
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.360
- HYPOXIA+0.310
- TGF_BETA_SIGNALING+0.300
- ANDROGEN_RESPONSE+0.270
- UV_RESPONSE_DN+0.270
- KRAS_SIGNALING_DN+0.260
- TNFA_SIGNALING_VIA_NFKB+0.240
- PI3K_AKT_MTOR_SIGNALING+0.170
Top 10 suppressed
- MYC_TARGETS_V2-0.540
- MYC_TARGETS_V1-0.440
- INTERFERON_ALPHA_RESPONSE-0.430
- E2F_TARGETS-0.400
- G2M_CHECKPOINT-0.320
- OXIDATIVE_PHOSPHORYLATION-0.320
- DNA_REPAIR-0.310
- FATTY_ACID_METABOLISM-0.280
- ADIPOGENESIS-0.270
- COAGULATION-0.260
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 544dbca2-f436-4cb7-9e11-572ead91d28d | — | — | 0.778 |
| 2 | TCGA-56-8308-01A-11R-2296-07 | — | cohortSQ2 | 0.772 |
| 3 | MNG435 | — | — | 0.769 |
| 4 | f65f4ed5-9726-4eff-8638-63752686d2c9 | — | — | 0.767 |
| 5 | TCGA-P6-A5OF-01 | Adrenocortical Carcinoma | Adrenocortical Carcinoma, Usual Type | 0.766 |
| 6 | TCGA-A1-A0SH-01A-11R-A084-07 | — | A | 0.759 |
| 7 | TCGA-EW-A1IX-01A-12R-A144-07 | — | A | 0.757 |
| 8 | TCGA-AR-A2LM-01A-11R-A180-07 | — | A | 0.757 |
| 9 | TCGA-HD-7831-01A-11R-2132-07 | — | — | 0.757 |
| 10 | SRR8613703 | — | D | 0.756 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 25 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| HEDGEHOG_SIGNALING | 0.390 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.370 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.360 | Inavolisib | — uncovered |
| HYPOXIA | 0.310 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.300 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.270 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.270 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.260 | Remibrutinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.240 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.170 | Inavolisib | — uncovered |
| APOPTOSIS | 0.140 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.140 | Inavolisib | — uncovered |
| MYOGENESIS | 0.130 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.110 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.100 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_UP | 0.100 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.100 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.090 | Remibrutinib | — uncovered |
| ANGIOGENESIS | 0.070 | Remibrutinib | — uncovered |
| APICAL_JUNCTION | 0.070 | Inavolisib | — uncovered |